GRAIL
The Vice President of Clinical Development provides enterprise leadership in defining and executing GRAIL's clinical development strategy and operations. This role oversees the governance and delivery of clinical studies across all phases, guiding strategic decisions that support regulatory success and product advancement. The position drives organizational excellence, cultivates talent, and represents Clinical Development in enterprise, regulatory, and external partnership settings.
Headquarters
Menlo Park, California, United States
Company Size
1001-5000 employees
Founded
2016
GRAIL, LLC is a healthcare company focused on detecting cancer early, when it can be cured. It develops blood-based multi‑cancer early detection tests (notably the Galleri test) that use high‑intensity sequencing of cell‑free DNA methylation patterns and machine learning to identify cancer signals across many tumor types. GRAIL partners with clinicians, health systems, and researchers to bring earlier diagnosis and population‑level screening into clinical practice.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for GRAIL.
GRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026
5 hours ago
Vice President, Clinical Development
Tarsus Pharmaceuticals
Vice President, Clinical Development
Tarsus Pharmaceuticals
Senior Vice President Clinical Development
Qpex Biopharma
Vice President, Clinical Development
Tarsus Pharmaceuticals
Vice President, Clinical Development (Oncology)
allogene
Vice President, Clinical Research
Leica Biosystems